QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Integra LifeSciences Holdings Corporation (IART)

Healthcare

No action
Fundamental
3
Sentiment
2
Technical
3

Do Nothing: qualitativeScore is 2 (below the required floor of 3) and the shadow sum-gate flag is false, so no bullish entry can be admitted regardless of the chart's +21% reclaim of the 20/50/200-day averages.

Analysis as of 2026-11-10· more than 2 trading days ago

Company overview

Integra LifeSciences Holdings Corporation is a medical technology company specializing in surgical implants and instruments for fields such as neurosurgery and limb reconstruction. It operates through Codman Specialty Surgical and Tissue Technologies segments, offering products like neurosurgical equipment and regenerative technology for wound treatment. The company distributes its products globally through direct sales and other channels.

Fundamental

fair
Fundamental3
Mixed fundamentals

Integra LifeSciences shows cash generation but faces high leverage and flat revenue growth, with a mixed valuation profile.

Integra LifeSciences is a leveraged, cash-generative medtech still working through the fallout of FDA quality-system failures and a $511M non-cash goodwill write-down. The 2026 interim trend is genuinely better - gross margin back above 52%, GAAP profitability restored, operating cash flow roughly tripled to $128.6M over nine months - and the October 2026 refinancing pushed maturities out to 2031/2033. But $2.0B of debt, about $1.75B of net debt, EBIT interest coverage below 1x and a 9.5% coupon on the new secured notes keep risk elevated, while revenue growth is essentially flat. Valuation is mixed: roughly 11.6x trailing EBITDA and 0.9x book look undemanding, free-cash-flow yield is about 9% on trailing numbers, and consensus targets sit roughly 29% above the current price - a mixed, show-me profile rather than a clean opportunity.

Sentiment

weak
Sentiment2
Weak sentiment

Sentiment is weak with unresolved regulatory issues and financial challenges, lacking a forward catalyst.

Dominant driver is a bearish ongoing_process catalyst: the 2026-10-02 Cincinnati flood guidance reset (announced confidence) remains unresolved with production recovery targeted for 2Q27, and the 2026-10-21 Q3 revenue miss with soft quarterly guidance sits just outside the actionable window. The sentiment delta is indeterminate — a measured baseline of polarity_score ≈ -0.17 is set against a signal-free recent sample and shows no genuine improvement — and no red-flag cap fired (the seven securities solicitations are law-firm marketing with regulator_confirmed_count 0), but with no market-rewarded bullish element the setup is weak and bearish-tilted.

Technical

fair
Technical3
Short-term repair

The stock has reclaimed key moving averages, showing a short-term repair but not a confirmed trend change.

Short-term repair inside a longer-term downtrend. From the 2026-10-27 close 11.99 (intraday low 11.72) IART has rallied +21% to 14.53, reclaiming SMA20 (13.16), SMA50 (14.45) and SMA200 (14.13) and pushing EMA9 (13.83) above EMA21 (13.64). MACD histogram has been positive and expanding for six straight sessions (+0.31 on 2026-11-10 vs -0.07 on 2026-10-27) and RSI14 56.0 leaves room before overbought. Offsetting: the MACD line is still fractionally below zero (-0.03), ADX 26.6 is trending but decelerating from 35.7 on 2026-10-28, Williams %R -20.1 says the tape is stretched after the run, and price remains ~29% below the 2026-07-28 high 20.49 with the 2026-10-02 Cincinnati flood / FY26 guidance reset unresolved. Net: mixed-to-constructive, score 3. The chart is not the disqualifier — the qualitative floor is.

You’re looking at 2026-11-10 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.